Production of chimeric antibodies by homologous recombination

• US 5,202,238 A
• Filed: 01/22/1990
• Issued: 04/13/1993
• Est. Priority Date: 10/27/1987
• Status: Expired due to Term

• Current Assignee: ONCOGEN 3005 FIRST AVENUE
• Original Assignee: Oncogen
• Inventors: Fell, H. Perry Jr., Folger-Bruce, Kim R.
• Primary Examiner(s): Chambers, Jasemine C.
• Application Number:
  US07/468,035
• Time in Patent Office: 1,177 Days
• Field of Search: 435/69.1, 435/192.3, 435/240.21, 435/240.26, 435/240.27, 435/317.1, 435/69.6, 435/69.7, 435/70.1, 435/70.21, 435/172.3, 530/387, 935/15, 935/111
• US Class Current: 435/69.6
• CPC Class Codes: C07K 16/462 Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/64 General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Abstract

A process for producing chimeric antibodies using novel recombinant DNA vectors and homologous recombination in vivo is described. The recombinant DNA constructs of the invention can be used to transfect antibody producing cells so that targeted homologous recombination occurs in the transfected cells leading to gene modification and the production of chimeric antibody molecules by the transfected cells.

Claims

1. A method for the production of a cell line expressing a chimeric antibody molecule, comprising:

(a) transfecting an antibody-producing lymphoid cell line with a first and second target vector, the first vector comprising;

(i) a replacement gene to modify a portion of the genomic sequence of an immunoglobulin heavy chain gene of the lymphoid cell line, and

(ii) a target sequence homologous to a DNA sequence adjacent to the immunoglobulin heavy chain sequence to be modified,

and the second vector comprising;

(i) a replacement gene to modify a portion of the genomic sequence of an immunoglobulin light chain gene of the lymphoid cell line and

(ii) a target sequence homologous to a DNA sequence adjacent to the immunoglobulin light chain sequence to be modified,

such that the first vector modifies the heavy chain gene of the cell line by site specific homologous recombination with genomic chromosomal DNA in vivo and the second vector modifies the light chain gene of the cell line by site specific homologous recombination with genomic chromosomal DNA in vivo; and

(b) selecting a transfectant which produces the chimeric antibody molecule.

2. A method for the production of a chimeric antibody molecule, comprising:

(a) culturing a chimeric-antibody-producing cell line which was prepared by transfecting an antibody-producing lymphoid cell line with a first and second target vector, the first vector comprising;

(i) a replacement gene to modify a portion of the genomic sequence of an immunoglobulin heavy chain gene of the lymphoid cell line, and

(ii) a target sequence homologous to a DNA sequence adjacent to the immunoglobulin heavy chain sequence to be modified,

and the second vector comprising;

(i) a replacement gene to modify a portion of the genomic sequence of an immunoglobulin light chain gene of the lymphoid cell line and

(ii) a target sequence homologous to a DNA sequence adjacent to the immunoglobulin light chain sequence to be modified,

such that the first vector modifies the heavy chain gene of the cell line by site specific homologous recombination with genomic chromosomal DNA in vivo and the second vector modifies the light chain gene of the cell line by site specific homologous recombination with genomic chromosomal DNA in vivo, and the chimeric antibody is expressed by the transfected cell line; and

(b) isolating the chimeric antibody molecule from the culture.